Not Signed In - FDA Issues Approvable Letter For NRP104 (lisdexamfetamine Dimesylate) For The Treatment Of ADHD
Tue, 10 Oct 2006 07:00 AM EST
... Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ) announced today that its collaborative partner New River Pharmaceuticals Inc. (Nasdaq: NRPH) has received an approvable letter from the U.S. Food and Drug Administration (FDA) for NRP104 (lisdexamfetamine dimesylate), for the treatment of pediatric Attention-Deficit/Hyperactivity Disorder (ADHD). [click link for full article] ...
Related Topics
- ADHD
- Population Issues
- Referral
- Tacrolimus ointment
- Thalidomide
- Mammography
- Guanfacine
- Treatment
- Carcinogens
- Social/Family Issues
- Laboratory Personnel Issues
- Family And Social Issues
- Culture / Cultural Issues
- Treatments
- Attention Deficit Hyperactivity Disorder (ADHD)
- Attention Deficit Hyperactivity (ADHD), Adult
- Women's Health
- Amantadine
- Pimecrolimus Cream 1%
- Dietary Guidelines
email this page
print this page
bookmark this page
feedback on this page
